Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

New ASCO/CCO mCRPC Treatment Guideline Incorporates Latest Approved Drugs

September 8th 2014

ASCO and CCO have released an updated guideline focused on the treatment of men with mCRPC that incorporates information about 6 recently approved drugs that have significantly changed the therapeutic landscape.

Targeting the Androgen Receptor: New Hope for Aggressive Forms of Prostate and Breast Cancer

September 5th 2014

Although hormone-targeting strategies have been a mainstay of prostate and breast cancer therapies for decades, an improved understanding of the mechanisms underlying these malignancies has led researchers to focus fresh attention on the complex activity of the androgen receptor (AR) as a point of attack.

Latest Evidence Guides Use of ADT with RT in Prostate Cancer

September 4th 2014

Practice-changing trends in the combined use of androgen deprivation therapy (ADT) and radiation therapy (RT) for the treatment of prostate cancer were highlighted recently in a review paper by Mack Roach III, MD, a professor of Radiation Oncology and Urology and chair of the Department of Radiation Oncology at the University of California, San Francisco.

Negative Cabozantinib Prostate Study Triggers Massive Exelixis Restructuring

September 2nd 2014

Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.

Enzalutamide + Sipuleucel-T Gives Immune Boost in mCRPC

September 1st 2014

Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.

Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study

August 30th 2014

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity

August 28th 2014

Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.

Pembrolizumab Combination Study Planned in Prostate Cancer

August 27th 2014

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

Urologist Perspectives Affect Treatments for Prostate Cancer

August 26th 2014

A physician's perspective, and the therapies he most often prescribes, can have a big influence on whether his patients with low-risk prostate cancer are treated or put on active surveillance, a study has found.

Prostate Cancer in Younger Men a Separate Phenotype

August 22nd 2014

Prostate cancer that emerges when a man is 55 years of age or younger is a distinct phenotype of the disease, and should be treated and researched accordingly,

In 2 Cancers, Robotic Versus Open Surgery is Explored

August 20th 2014

In recent studies, robotic-assisted surgery was explored as a treatment for both prostate and kidney cancers.

In Prostate Cancer, Depression Means Less Treatment, Worse Outcomes

August 19th 2014

Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival.

The Cognitive Error Paradigm

August 15th 2014

As fellows in oncology, we are constantly required to assimilate data, interpret diagnostic tests, decide on appropriate treatment regimens, and employ compassionate care in an increasingly truncated allotment of time.

Free Testosterone May Dictate Necessary Treatment in Prostate Cancer

August 8th 2014

Research from Chile suggests that low levels of free testosterone indicate that an apparently low-risk case of prostate cancer will require treatment.

Dr. Freedland on the Association Between Carbohydrates and Prostate Cancer Risk

August 6th 2014

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index, and prostate cancer risk.

AUA Adds Radium-223 to Treatment Guidelines for mCRPC

August 6th 2014

The American Urological Association (AUA) has added recommendations for the use of radium-223 to its treatment guidelines for castration-resistant prostate cancer

Dr. Brawer on Predicting Radical Prostatectomy Outcomes

July 22nd 2014

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

Dr. Petrylak on PSMA ADC for Patients with mCRPC

July 21st 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

Giants of Cancer Care Heralded: Ceremony Honors 2nd Annual Giants Class

July 16th 2014

The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.

Advanced Prostate Cancer Clinics Keep Urologists, Patients Together

July 10th 2014

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.